pembrolizumab,nivolumab
merck,bms
['biomarker', 'keytruda', 'opdivo']
schalper #aacr23 mok et al 2008 ipass progression-free survival in egfr-mutation+ versus - patients. working / not working in patients depending on the biomarker. points out pd-l1, for keytruda and opdivo resulted in a $8b drug.
Business development, marketing and sales professional in the life sciences, cancer diagnostics, and genomics fields. Blog: https://t.co/IeMzCogxlt. Opinions are my own.